RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales
RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving...
Robotrak Secures NMPA License for China’s First Smart Ophthalmic Navigation Laser
Robotrak, a Nanjing-based ophthalmic innovation platform, has secured a Category III medical device license from...
Sichuan Biokin Launches Phase III Trial for Bispecific ADC BL-B01D1 in Lung Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a...
Yixintang Partners with Huawei Cloud to Drive Digital Transformation in Pharma Retail
Yixintang Pharmaceutical Group Co., Ltd. (SHE: 002727), a prominent pharmaceutical retail chain in China, has...
Ant Group Eyes Acquisition of Leading Internet Healthcare Platform Haodf.com
Ant Group, the China-based fintech powerhouse, is reportedly pursuing the acquisition of Haodf.com, one of...
CARsgen Completes Patient Enrollment for Phase II Trial of CT041 in Advanced Gastric Cancer
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a leading China-based developer of chimeric antigen receptor (CAR)-T...
Bio-Thera Solutions Expands Reach with New Licensing Deal for Biosimilar BAT2306
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a new licensing agreement with Russian firm...
Evotec to Cut 400 Jobs Amid R&D Slowdown and Corporate Restructuring
Evotec SE (NASDAQ: EVO), a Germany-based Contract Research and Development Organization (CRO/CDMO), has announced plans...
RemeGen Appoints He Ruyi as Chief Strategy Officer, Transitioning from CMO Role
RemeGen (HKG: 9995), a China-based pharmaceutical company, has appointed He Ruyi as its new Chief...
Kelun Pharmaceutical’s Sacituzumab Tirumotecan Receives Priority Review for NSCLC Treatment
Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) has announced that its drug sacituzumab tirumotecan (SKB264/MK-2870)...
Huadong Medicine Secures Licensing Deal with IMBiologics for Autoimmune Drug Candidates
Huadong Medicine Co., Ltd. (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
Lykos Therapeutics Faces Setback as FDA Rejects Midomafetamine for PTSD Treatment
Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s...
Chugai Seeks Approval for Elevidys Gene Therapy in Japan, Targeting Duchenne Muscular Dystrophy
Chugai Pharmaceutical Co., Ltd. (TYO: 4519), a subsidiary of Roche, has submitted a product approval...
Staidson Launches Phase Ia Trial for STSP-0902 Injection in Oligoasthenozoospermia
Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from...
Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-2106 in Primary Sjögren’s Syndrome
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...
Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder
Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...
Sino Medical Secures Moroccan Approvals for NC Rockstar Catheter and HT Supreme Stent System
Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...
Vimgreen Pharma Launches Phase II Trial for A2AR Antagonist VG081821AC in Parkinson’s Disease
Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...
Gilead Secures FDA Accelerated Approval for Livdelzi in Liver Disease Treatment
Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...
Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...